The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Open accessAbstract
BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction. METHODS: We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects meta-analysis to estimate the effect of SGLT2 inhibitors on various clinical endpoints in heart failure The primary endpoint for this meta-analysis was time from randomisation to the occurrence of the composite of cardiovascular death or hospitalisation for heart failure. We assessed heterogeneity in treatment effects for the primary endpoint across subgroups of interest. This study is registered with PROSPERO, CRD42022327527. FINDINGS: Among 12 251 participants from DELIVER and EMPEROR-Preserved, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0·80 [95% CI 0·73-0·87]) with consistent reductions in both components: cardiovascular death (0·88 [0·77-1·00]) and first hospitalisation for heart failure (0·74 [0·67-0·83]). In the broader context of the five trials of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalisation for heart failure (0·77 [0·72-0·82]), cardiovascular death (0·87 [0·79-0·95]), first hospitalisation for heart failure (0·72 [0·67-0·78]), and all-cause mortality (0·92 [0·86-0·99]). These treatment effects for each of the studied endpoints were consistently observed in both the trials of heart failure with mildly reduced or preserved ejection fraction and across all five trials. Treatment effects on the primary endpoint were generally consistent across the 14 subgroups examined, including ejection fraction. INTERPRETATION: SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a large meta-analysis (308) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [308]
The cited source says what the claim attributes to it.
In the citing paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
The cited source says what the claim attributes to it.
In the citing paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [535]
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“A large recent meta-analysis (227) including data from EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) included 21,947 patients and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, fi r”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
In the citing paper
“The fi ndings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all fi ve trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationSolomon, S. D., Anavekar, N. S., Skali, H., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Wang, D., Pocock, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.561423 · Cited by 873
Self-citation
Research works printed but not linked: 1
- Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 · DOI · Paper page
Cited by
Sorted by citations
Items 201–300 of 1,000
Metra, M., Tomasoni, D., Adamo, M., Amir, O., Anker, S. D., Bayés‐Genís, A., Böehm, M., Butler, J., Chioncel, O. D., Filippatos, G. S., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15408 · Cited by 24
Patoulias, D., Fragakis, N., & Rizzo, M. (2022) · Life · doi:10.3390/life12122062 · Cited by 19
Pistelli, L., Parisi, F., Correale, M., Cocuzza, F., Campanella, F., Ferrari, T. D., Crea, P., Sarro, R. D., Cognata, O. M. L., Ceratti, S., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010379 · Cited by 19
Clephas, P. R. D., Aydin, D., Radhoe, S. P., & Brugts, J. J. (2023) · Sensors · doi:10.3390/s23031364 · Cited by 18
Ferrannini, E., Solini, A., Baldi, S., Scozzaro, T., Polidori, D., Natali, A., & Hansen, M. K. (2023) · Diabetes · doi:10.2337/db23-0448 · Cited by 18
Proteomic Prediction of Incident Heart Failure and Its Main Subtypes
Emilsson, V., Jonsson, B. G., Austin, T. R., Guðmundsdóttir, V., Axelsson, G. T., Frick, E. A., Jónmundsson, Þ., Steindorsdottir, A. E., Loureiro, J., Brody, J. A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3086 · Cited by 19
Beal, B., Schutte, A. E., & Neuen, B. L. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01281-1 · Cited by 21
Doi, S., Reddy, Y. N. V., Jensen, M. D., Smith, J. R., & Borlaug, B. A. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf027 · Cited by 18
Nyström, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15696 · Cited by 18
Bertoluci, M. C., Júnior, W. S. D. S., Valente, F., Araujo, L. R., Lyra, R., de Castro, J. J., Raposo, J. F., Miranda, P. A. C., Boguszewski, C. L., Hohl, A., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01121-x · Cited by 22
Fudim, M., Litwin, S. E., Borlaug, B. A., Mohan, R. C., Price, M. J., Fail, P. S., Zirakashvili, T., Shaburishvili, T., Goyal, P., Hummel, S. L., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.12.010 · Cited by 17
Self-citationHiraiwa, H., Okumura, T., & Murohara, T. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00641-9 · Cited by 19
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 18
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
Butt, J. H., Docherty, K. F., Claggett, B. L., Desai, A. S., Fang, J. C.-T., Petersson, M., Langkilde, A. M., de Boer, R. A., Honorio, J. W. C., Hernandez, A. F., et al. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2022.11.014 · Cited by 19
Self-citationRole of macrophage polarization in heart failure and traditional Chinese medicine treatment
Zhu, Z., Wang, M., Lu, S., Dai, S., & Liu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1434654 · Cited by 16
Cherbi, M., Lairez, O., Baudry, G., Gautier, P., Roubille, F., & Delmas, C. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039105 · Cited by 19
Vaduganathan, M., Claggett, B. L., Chatur, S., Desai, A. S., Jhund, P. S., Vardeny, O., Merkely, B. P., Martínez, F. A., Colet, J. C., Saraiva, J. F. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04037-3 · Cited by 18
Self-citationNeumiller, J. J., Lienhard, F. J., Alicic, R. Z., & Tuttle, K. R. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.106 · Cited by 17
Lodato, M., Plaisance, V., Pawlowski, V., Kwapich, M., Barras, A., Buissart, E., Dalle, S., Szunerits, S., Vicogne, J., Boukherroub, R., et al. (2023) · Cells · doi:10.3390/cells12060940 · Cited by 17
Park, S., Jeong, H. E., Lee, H., You, S. C., & Shin, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01896-3 · Cited by 17
Ferreira, J. P., Blatchford, J., Teerlink, J. R., Kosiborod, M., Angermann, C. E., Biegus, J., Collins, S. P., Tromp, J., Nassif, M. E., Psotka, M. A., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2982 · Cited by 16
Self-citationOriecuia, C., Tomasoni, D., Sala, I., Bonfioli, G. B., Adamo, M., Gussago, C., Lombardi, C., Pagnesi, M., Savarese, G., Metra, M., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad088 · Cited by 17
Kittipibul, V., Vaduganathan, M., Ikeaba, U., Chiswell, K., Butler, J., DeVore, A. D., Heidenreich, P. A., Huang, J., Kittleson, M. M., Maddox, K. E. J., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.04.003 · Cited by 17
Self-citationLandolfo, M., Spannella, F., Giulietti, F., Ortensi, B., Stella, L., Carlucci, M. A., Galeazzi, R., Turchi, F., Luconi, M. P., Zampa, R., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02391-z · Cited by 19
Lee, H., Chan, Y., Chuang, C., Li, P., Yeh, Y., Hsiao, F., Peng, J., & See, L. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad004 · Cited by 15
NHC/ SHA 2023 Focused update of the 2019 guidelines for the management of heart failure
Habeeb, W. A., Tash, A. A., Elasfar, A., Almasood, A. S., Bakhsh, A., Elshaer, F., Ayoubi, F. A., Alghalaini, K., Alqaseer, M., Alhussein, M., et al. (2023) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1334 · Cited by 16
Marzo, V. D., Savarese, G., Porto, I., Metra, M., & Ameri, P. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001504 · Cited by 14
Muñoz, D. R., Crespo‐Leiro, M. G., Lozano, I. F., Gómez, J. L. Z., Peinado, R., Manzano, L., Bagudá, J. D. J., Castillo, A. M. D., Arribas, F., & Bodes, R. S. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14488 · Cited by 15
Kommu, S. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001511 · Cited by 18
Lv, C., Hu, C., Zhu, C., Wan, X., Chen, C., Ji, X., Qin, Y., Lü, L., & Guo, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115963 · Cited by 15
Kongmalai, T., Hadnorntun, P., Leelahavarong, P., Kongmalai, P., Srinonprasert, V., Chirakarnjanakorn, S., Chaikledkaew, U., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1216160 · Cited by 18
Cardiorespiratory Fitness and Risk of Heart Failure with Preserved Ejection Fraction
Kokkinos, P. F., Faselis, C. J., Pittaras, A. E., Samuel, I. B. H., Lavie, C. J., Vargas, J. D., LaMonte, M. J., Franklin, B. A., Assimes, T. L., Murphy, R., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3117 · Cited by 15
Horiuchi, Y., Asami, M., Yahagi, K., Oshima, A., Gonda, Y., Yoshiura, D., Komiyama, K., Yuzawa, H., Tanaka, J., Aoki, J., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061670 · Cited by 17
Fazio, S., Mercurio, V., Fazio, V., Ruvolo, A., & Affuso, F. (2024) · Biomedicines · doi:10.3390/biomedicines12040806 · Cited by 17
Treatment strategies for diuretic resistance in patients with heart failure
Horiuchi, Y., & Wettersten, N. W. (2024) · Journal of Cardiology · doi:10.1016/j.jjcc.2024.06.005 · Cited by 15
Proximal tubule hypertrophy and hyperfunction: a novel pathophysiological feature in disease states
Kanbay, M., Çöpür, S., Güldan, M., Özbek, L., Hatipoğlu, A., Covic, A. C., Mallamaci, F., & Zoccali, C. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae195 · Cited by 20
SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review
Sloan, L. A. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2418795 · Cited by 16
Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells
Zhang, Q., Dai, J., Liu, T., Rao, W., Li, D., Gu, Z., Huang, L., Wang, J., & Hou, X. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05134-6 · Cited by 15
Leontsinis, I., Farmakis, D. T., Avramidis, D., Andrikou, E., Valatsou, A., Gartzonikas, I. K., Doundoulakis, I., Zarifis, Ι., Karpouzis, I., Kafkala, K., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.03.006 · Cited by 15
Ostrominski, J. W., & Vaduganathan, M. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.04.035 · Cited by 21
Self-citationSodium-glucose cotransporter-2 inhibitor use in patients with a Fontan circulation
Gaydos, S. S., McHugh, K. E., Woodard, F. K., Judd, R. N., Brenzel, T., Henderson, H., Savage, A., Atz, A. M., & Gregg, D. (2025) · Cardiology in the Young · doi:10.1017/s1047951125000514 · Cited by 14
Jones, N. R., Smith, M. C., Yang, Y., Hobbs, R. F., & Taylor, C. J. (2025) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2025.100734 · Cited by 14
Docherty, K. F., Heywood, B. R., Bayés‐Genís, A., Campbell, R. T., Henderson, A. D., Jhund, P. S., Køber, L., Schou, M., Solomon, S. D., Vaduganathan, M., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf675 · Cited by 15
Self-citationThe current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
Scheen, A. J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2210673 · Cited by 15
Kasprzak, J. D., Gorczyca-Głowacka, I., Sobczak, M., Barylski, M., Dróżdż, J., Filipiak, K. J., Kapłon‐Cieślicka, A., Lelonek, M., Mamcarz, A., Ochijewicz, D., et al. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0110 · Cited by 17
Locomotor and respiratory muscle abnormalities in HFrEF and HFpEF
Mangner, N., Winzer, E. B., Linke, A. H.-P., & Adams, V. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1149065 · Cited by 14
Trial sequential analysis methodology for interpreting meta-analytical findings
Greco, A., & Capodanno, D. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.12.029 · Cited by 14
Dapagliflozin and Timing of Prior Heart Failure Hospitalization
Butt, J. H., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., Martínez, F. A., et al. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.01.018 · Cited by 14
Self-citationEffects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure
Bhatt, A. S., Bhatt, D. L., Steg, P. G., Szarek, M. J., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.06.036 · Cited by 14
Self-citationSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Andreea, M. M., Surabhi, S., Popescu, R.-I., Ciobotaru, L. M., Nicolae, C., Emil, T., & Tiberiu, N. I. (2023) · Medicina · doi:10.3390/medicina59040742 · Cited by 17
Greene, S. J., Butler, J., & Fonarow, G. C. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0038 · Cited by 13
Heart failure in the elderly: epidemiology, mechanisms, and management
de Boer, R. A., Abdellatif, M., Bauersachs, J. K., & Roger, V. L. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag110 · Cited by 20
Fazio, S., Mercurio, V., Affuso, F., & Bellavite, P. (2023) · Biomedicines · doi:10.3390/biomedicines11112928 · Cited by 13
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2023) · Nefrología · doi:10.1016/j.nefro.2023.11.001 · Cited by 14
Varshney, A. S., Calma, J., Kalwani, N. M., Hsiao, S., Sallam, K., Cao, F., Din, N., Schirmer, J., Bhatt, A. S., Ambrosy, A. P., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.12.018 · Cited by 13
Mancusi, C., Basile, C., Spaccarotella, C., Gargiulo, G., Fucile, I., Paolillo, S., Gargiulo, P., Santoro, C., Manzi, L., Marzano, F., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00629-1 · Cited by 15
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Cases, A., Cigarrán, S., Górriz, J. L., & Núñez, J. E. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.03.011 · Cited by 15
Optimising Transitional Care Following a Heart Failure Hospitalisation in Australia
Sindone, A. P., Driscoll, A. L., Audehm, R. G., Sverdlov, A. L., McVeigh, J., Chan, W. P. A., Hickey, A., Hopper, I., Chang, T., Maiorana, A., et al. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2023.11.029 · Cited by 16
Ostrominski, J. W., Solomon, S. D., & Vaduganathan, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae414 · Cited by 14
Self-citationContemporary treatment options in heart failure with preserved ejection fraction
Peikert, A., & Solomon, S. D. (2024) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeae201 · Cited by 13
Self-citationFerreira, J. P., Oliveira, A., Vasques‐Nóvoa, F., Leite, A. R., Mendonça, L., Zannad, F. M., Butler, J., Leite-Moreira, A. F., Saraiva, F. A., & Neves, J. S. (2024) · American Journal of Nephrology · doi:10.1159/000541686 · Cited by 13
SGLT2 Inhibition Induces Cardioprotection by Increasing Parasympathetic Activity
Васильевна, Б. М., KORSAK, A. S., He, Z., Gourine, A. V., Davidson, S. M., & Yellon, D. M. (2024) · Circulation Research · doi:10.1161/circresaha.124.324708 · Cited by 13
Lee, K., Noh, J. H., Park, S., Choi, K. M., Kang, S., Won, K. C., Cho, H., Moon, M. K., & Korean Society of Heart Failure (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0420 · Cited by 13
Current Treatment of Heart Failure with Preserved Ejection Fraction
Riccardi, M., D’Elia, E., Lombardi, C., Savarese, G., Gori, M., Oliva, F. G., Volterrani, M., Senni, M., Metra, M., & Inciardi, R. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155406 · Cited by 13
SGLT-2 Inhibitors and GLP-1 Receptor Agonists as Combination Therapy in Type 2 Diabetes
Liakos, A., Karagiannis, T., Avgerinos, I., & Bekiari, E. (2026) · Current Diabetes Reports · doi:10.1007/s11892-025-01616-z · Cited by 16
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Aguiar‐Neves, I., Santos‐Ferreira, D., & Fontes‐Carvalho, R. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401001 · Cited by 16
Weeks, K. L., Kiriazis, H., Wadley, G. D., Masterman, E. I., Sergienko, N. M., Raaijmakers, A. J. A., Trewin, A. J., Harmawan, C. A., Yildiz, G. S., Liu, Y., et al. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02397-2 · Cited by 12
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 13
Bhatt, A. S., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Anand, I. S., Desai, A. S., Fang, J. C.-T., Hernandez, A. F., Jhund, P. S., Kosiborod, M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032279 · Cited by 15
Self-citationInciardi, R. M., Vaduganathan, M., Lombardi, C., Gussago, C., Agostoni, P., Ameri, P., Aspromonte, N., Calò, L., Cameli, M., Carluccio, E., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3260 · Cited by 12
Self-citationWu, C., Shah, B. R., Sharma, A., Sheng, Y., Liu, P. P., Kopp, A., Saskin, R., Edwards, J. D., & Swardfager, W. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3464 · Cited by 12
Shahid, I., Khan, M. S., Butler, J., Fonarow, G. C., & Greene, S. J. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10481-7 · Cited by 16
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 15
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 12
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 15
Gu, J., Zheng, Z., Li, J. S., Wu, S., Sun, H., Pang, J., & Chen, Y. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf047 · Cited by 12
Chen, H., Yang, Y., Meng, R., & Liu, X. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14297 · Cited by 13
Belančić, A., & Majanović, S. K. (2023) · Diabetology · doi:10.3390/diabetology4030022 · Cited by 12
Wang, H., Gao, C., Guignard‐Duff, M., Cole, C., Hall, C., Baruah, R., Das, S., Gao, H., Mamza, J. B., Lang, C. C., et al. (2025) · Heart · doi:10.1136/heartjnl-2024-324160 · Cited by 13
Peikert, A., Vacca, A., Norata, G. D., Schiattarella, G. G., & Osto, E. (2026) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.012674 · Cited by 16
Nakao, Y. M., Nakao, K., Nadarajah, R., Banerjee, A., Fonarow, G. C., Petrie, M. C., Rahimi, K., Wu, J., & Gale, C. P. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102164 · Cited by 11
Pabón, M. A., Claggett, B. L., Wang, X., Miao, Z. M., Chatur, S., Bhatt, A. S., Vaduganathan, M., Fang, J. C., Desai, A. S., Jhund, P. S., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3001 · Cited by 12
Self-citationAcute effects of β-hydroxybutyrate on left ventricular function in young, healthy adults
Oneglia, A. P., Young, B. E., Cipher, D. J., Zaha, V. G., & Nelson, M. D. (2023) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00630.2023 · Cited by 12
Galectin-4 is associated with diabetes and obesity in a heart failure population
Dieden, A., Gudmundsson, P., Korduner, J., Molvin, J., Zaghi, A., Nezami, Z., Bachus, E., Holm, H., Jujić, A., & Magnusson, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-47426-9 · Cited by 11
The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development
Davidson, M. H., Hsieh, A., Dicklin, M. R., & Maki, K. C. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.12.005 · Cited by 14
Zou, X., Shi, Q., & Li, S. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12597 · Cited by 11
Balestrieri, G., Limonta, R., Ponti, E., Merlo, A., Sciatti, E., D’Isa, S., Gori, M., Casu, G., Giannattasio, C., Senni, M., et al. (2024) · Cardiac failure review · doi:10.15420/cfr.2023.13 · Cited by 15
An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease
Tumelty, E. H., Chung, I., Hussain, S., Ali, M. A., Addada, H., & Banerjee, D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504144 · Cited by 11
Dixit, N. M., Truong, K. P., Vaduganathan, M., Ziaeian, B., & Fonarow, G. C. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.03.006 · Cited by 11
Self-citationHuang, Q., Shi, W., Wang, M., Zhang, L., Zhang, Y., Hu, Y. F., Pan, S., Ling, B., Zhu, H., Xiao, W., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110429 · Cited by 11
Zahir, D., Bonde, A. N., Fosbøl, E. L., Garred, C. H., Gislason, G., Elmegaard, M., Knigge, P., Torp-Pedersen, C. T., Andersson, C., Pfeffer, M. A., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14933 · Cited by 11
Self-citationShah, S., Mushahid, H., Salman, A., Farhan, S. H., Latif, F., Siddiqi, R. L., Nashwan, A. J., Abramov, D., & Minhas, A. M. K. (2025) · Drugs & Aging · doi:10.1007/s40266-025-01183-8 · Cited by 13
Self-citationSevere Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum
Inciardi, R. M., Lu, H. Y., Claggett, B. L., Desai, A. S., Jhund, P. S., Lam, C. S. P., Kosiborod, M., Inzucchi, S. E., Martínez, F. A., de Boer, R. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.11.023 · Cited by 12
Self-citationVranken, N. P. A., Li, X., Bouman, H. J., Mourmans, S. G. J., Achten, A., Aizpurua, A. B., Rocca, H. B., Knackstedt, C., van Empel, V. P. M., & Weerts, J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02708-6 · Cited by 14
Risk and temporal trends of heart failure subtypes in rheumatoid arthritis
Johnson, T. M., Yang, Y., Roul, P., Frideres, H., Baker, J. F., Sauer, B. C., Cannon, G. W., Kunkel, G. A., Bookani, K. R., Mikuls, T. R., et al. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152816 · Cited by 12
Palazzuoli, A., Correale, M., Iacoviello, M., & Gronda, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020693 · Cited by 11
Stumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Kani, R., Miyamoto, Y., Saito, T., Watanabe, A., Matsubara, K., Ejiri, K., Iwagami, M., Slipczuk, L., Hosseini, K., Fujisaki, T., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133079 · Cited by 10
Wahinya, M., & Khan, Z. U. (2023) · Cureus · doi:10.7759/cureus.37388 · Cited by 10
Wang, Q., Yu, J., Deng, W., Liu, C., Yang, J., Li, Y., Cai, G., Chen, X., & Dong, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372421 · Cited by 10
Metadata
- Authors
- Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D.
- Affiliations
- Brigham and Women's Hospital (US)
- British Heart Foundation (GB)
- Duke Medical Center (US)
- Yale University (US)
- University of Missouri–Kansas City (US)
- National University of Singapore (SG)
- Northwestern University (US)
- Corresponding author
- Solomon, Scott D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 400
- Issue
- 10354
- Pages
- 757-767
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4293353625
- Cited by
- 996
- References
- 24
- Citations by year
- 2026: 215 · 2025: 203 · 2024: 279 · 2023: 257 · 2022: 42
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-14)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, public-domain)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, public-domain)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company (NCT03057951)
- Pfizer
- AstraZeneca
- Sanofi
- National Institutes of Health
- Defense Acquisition Program Administration
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, DAPA-HF, EMPEROR-Preserved, EMPEROR-Reduced, cardiovascular risk stratification, treatment effect heterogeneity
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Stroke Volume, Randomized Controlled Trials as Topic, Ventricular Function, Left, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
